Corbus Pharmaceuticals GAAP EPS of -$1.25 beats by $0.40
Source: SeekingAlpha
2026-03-09 07:38:17 ET
More on Corbus Pharmaceuticals
- Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript
- Corbus declines following early-stage results on oral obesity asset CRB-913
- Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Corbus Pharmaceuticals GAAP EPS of -$1.25 beats by $0.40
Corbus Pharmaceuticals Holdings Inc.
NASDAQ: CRBP
CRBP Trading
-4.92% G/L:
$8.895 Last:
50,281 Volume:
$8.98 Open:
CRBP Latest News
March 18, 2026 08:00:00 am
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
March 09, 2026 07:30:00 am
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
February 12, 2026 08:00:00 am
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
January 05, 2026 07:30:00 am
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
CRBP Stock Data
$140,073,235
13,638,710
0.21%
53
N/A
Biotechnology & Life Sciences
Healthcare
US
Norwood
